CRA consultant Becky Davis recently presented “GLP-1s: Riding the Wave of Innovative Medications” at Asembia’s AXS25 Summit, which looked at the evolution of the GLP-1 category, and what might be in store for future payer management.
Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...

